Prevention of hydrocephalus with a small oligonucleotide

Area of Science:

• Biochemistry
• Genetics
• Pediatric Neurology

Background:

• Hydrocephalus is a frequent pediatric neurological disorder, often linked to monogenic syndromes.
• Current treatments like shunts have complex aftercare, and molecular therapies remain underexplored.
• Schinzel-Giedion Syndrome (SGS) is a monogenic disorder caused by elevated SETBP1 protein.

Purpose of the Study:

• To investigate oligonucleotides as a potential therapeutic drug class for preventing hydrocephalus.
• To assess the efficacy of antisense oligonucleotides targeting SETBP1 in a mouse model of SGS.

Main Methods:

• Utilized a mouse model engineered to express mutant human SETBP1, exhibiting hydrocephalus.
• Administered antisense oligonucleotides specifically targeting SETBP1 to the affected mice.
• Compared hydrocephalus incidence, severity, and long-term survival rates against mock-treated controls.

Main Results:

• Treatment with antisense oligonucleotides targeting SETBP1 significantly prevented hydrocephalus in the SGS mouse model.
• A notable reduction in hydrocephalus was observed compared to control groups.
• Oligonucleotide intervention led to improved long-term survival in the treated mice.

Conclusions:

• Hydrocephalus associated with Schinzel-Giedion Syndrome is preventable using oligonucleotide-based therapy.
• Antisense oligonucleotides targeting SETBP1 represent a viable therapeutic strategy for this condition.
• This approach may offer broader applications for treating monogenic syndromes causing hydrocephalus.